Sign In
Buy ALNA
$0.0270
+0 (+0%)
At Close: Feb 07, 2023
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
07:00am, Tuesday, 09'th Mar 2021
-- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a trials for hyp
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March
08:00am, Wednesday, 24'th Feb 2021
NEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral en
7 Penny Stocks That Actually Have Buy Ratings
01:22pm, Wednesday, 03'rd Feb 2021
Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.
Has Allena Pharmaceuticals (ALNA) Outpaced Other Medical Stocks This Year?
12:48pm, Tuesday, 12'th Jan 2021
Is (ALNA) Outperforming Other Medical Stocks This Year?
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in January
08:00am, Monday, 04'th Jan 2021
NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e
Steven Cohen Boots Health Care Exposure With 2 Biotech Stocks
05:27pm, Friday, 11'th Dec 2020
Billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, established a 14.37% stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) and a 7.96%
Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million
09:47pm, Tuesday, 01'st Dec 2020
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e
Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering
05:00pm, Tuesday, 01'st Dec 2020
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e
Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D.
08:00am, Tuesday, 01'st Dec 2020
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e
Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346
08:00am, Monday, 30'th Nov 2020
-- Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated -- -- Non- A bsorption o f ALLN-346 Demonstrated -- -- Advancing to Phase 1b Multiple - Ascending Dose Study and Phase 2 Proof-of-Conce
Allena Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
08:00am, Monday, 09'th Nov 2020
-- Presented Data at 53 rd Annual Meeting of the American Society of Nephrology (ASN) Highlighting Consistent Treatment Effects Across Phase 2 and 3 Clinical Trials of Reloxaliase in E nteric H yperox
Allena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in November
08:01am, Tuesday, 03'rd Nov 2020
NEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral e
Allena Pharmaceuticals (ALNA) Investor Presentation - Slideshow
06:06pm, Thursday, 13'th Aug 2020
The following slide deck was published by Allena Pharmaceuticals, Inc. in conjunction with this event..
Jefferies Maintains Their Buy Rating on Allena Pharmaceuticals (ALNA) - Markets
09:56pm, Sunday, 09'th Aug 2020
Jefferies analyst Chris Howerton maintained a Buy rating on Allena Pharmaceuticals (ALNA – Research Report) on August 5 and set
Allena Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update
12:00pm, Wednesday, 05'th Aug 2020
\-- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 –- \-- Initiated Phase 1 Clinical Trial of ALLN-346; Initial Data Expected in the Fourth Quarter of 2020
